NCT01767402View on ClinicalTrials.gov

Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

November 30, 2004

Study Completion Date

November 30, 2004

Conditions
Pneumococcal Disease
Interventions
BIOLOGICAL

PhtD vaccine with/without adjuvant

Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.

BIOLOGICAL

Pneumovax 23TM

One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.

BIOLOGICAL

NaCl

One dose administered intramuscularly in the deltoid region of the right arm at month 2.

Trial Locations (1)

1200

GSK Investigational Site, Brussels

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY